Corcept Therapeutics CORT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's operating income?
- Corcept Therapeutics (CORT) reported operating income of -$49.6M in Q1 2026.
- How has Corcept Therapeutics's operating income changed year-over-year?
- Corcept Therapeutics's operating income decreased by 1552.0% year-over-year, from $3.42M to -$49.6M.
- What is the long-term trend for Corcept Therapeutics's operating income?
- Over 4 years (2021 to 2025), Corcept Therapeutics's operating income has grown at a -22.5% compound annual growth rate (CAGR), from $124.48M to $44.8M.
- What does operating income mean?
- Profit earned from core business operations before interest and taxes.
- How do you interpret operating income?
- Higher operating income demonstrates strong core profitability and effective management of operating expenses.
- How does operating income compare across companies?
- A primary metric for comparing operational efficiency between companies in the same sector.